IMTX icon

Immatics

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 25%
Negative

Positive
Seeking Alpha
6 days ago
Immatics: Multiple Clinical Catalysts In Q4'25 And 2026
IMTX is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Anzu-cel offers advantages over IOVA's Amtagvi, including less invasive cell collection, faster turnaround, and no need for high-dose IL-2. Phase 1b data show a 56% objective response rate and 91% disease control rate in melanoma patients treated with IMTX's therapy.
Immatics: Multiple Clinical Catalysts In Q4'25 And 2026
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for August 15th
IMTX, ERJ and BFIN have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2025.
New Strong Sell Stocks for August 15th
Negative
Zacks Investment Research
2 months ago
Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.18 per share a year ago.
Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Immatics Announces Second Quarter 2025 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, August 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today provided a business update and reported financial results for the quarter ended June 30, 2025.
Immatics Announces Second Quarter 2025 Financial Results and Business Update
Positive
Zacks Investment Research
4 months ago
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
Neutral
GlobeNewsWire
4 months ago
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Stafford , Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor.
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Neutral
GlobeNewsWire
5 months ago
Immatics Announces First Quarter 2025 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2025.
Immatics Announces First Quarter 2025 Financial Results and Business Update
Neutral
GlobeNewsWire
5 months ago
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois.
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Negative
Seeking Alpha
6 months ago
Immatics N.V.: Trading Below Cash, But Not Without Reason
Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert. Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty.
Immatics N.V.: Trading Below Cash, But Not Without Reason
Neutral
GlobeNewsWire
6 months ago
Immatics Announces Full Year 2024 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.
Immatics Announces Full Year 2024 Financial Results and Business Update